metaMe Health, Inc.

metaMe Health is a pioneer in developing Prescription Digital Therapeutics (PDTs). In 2022, our work was recognized by being included on the “50 on Fire” list of up-and-coming Chicago companies, being named one of the Top 150 most promising Digital Health Companies of 2022 nationwide by CBInsights, and being selected as a finalist in the LyfeBulb-Bristol Myers Squibb Inflammatory Bowel Disease Challenge. In 2021, our lead product Regulora® became the first FDA-cleared PDT specifically for abdominal pain associated with irritable bowel syndrome (IBS) in adults. More than 30 million Americans are affected by IBS, and the abdominal pain, diarrhea, and/or constipation that comes with it. Regulora provides relief by digitizing a standardized Brain-Gut therapy approach that has been clinically proven to be effective in reducing IBS symptoms.